|
Lonza Acquires Viral Vaccine and Vector Manufacturer Vivante GMP Solutions
Lonza enters the viral based-manufacturing market today with its purchase of Vivante GMP Solutions, Inc. The acquisition advances Lonza's strategy to broaden its biologics custom service offering for the growing viral vaccine and gene therapy markets. To read the rest of the press release, CLICK HERE
Non-Dilutive Funding Opportunities Seminar: Tap into New Large Scale Non-Dilutive Funding Opportunities
We are witnessing today a continuous movement by the National Institutes of Health (NIH) and the Department Of Defense (DOD) towards supporting the life science industry, with a greater understanding as to the industry's needs, focus, and difficulties. The scope of funding support given to industry R&D efforts from non-dilutive sources such as NIH and DOD covers the entire R&D cycle all the way to clinical research activities (Phase I, II and III).
Watch the full seminar |
